Summit Therapeutics to Participate in February Investor Conferences
February 02 2017 - 07:00AM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, announces
that company management will participate in three upcoming investor
conferences taking place in New York City in February.
- Canaccord Genuity Rare Disease and BioPharma One-on-One Day –
February 7, 2017
- BIO CEO & Investor Conference – February 13, 2017;
presentation at 10:30am EST
- SunTrust Robinson Humphrey Orphan Drug Day – February 14,
2017
For the Canaccord Genuity and SunTrust Robinson
Humphrey events, the Company will participate in one on one
meetings. A live audio webcast of the BIO CEO & Investor
Conference presentation will be available through the Investors
section on the Company’s website, www.summitplc.com. A replay of
the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit
Therapeutics Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
Tel: +44 (0)1235 443
951 +1 617 225 4455 |
Cairn Financial
Advisers LLP (Nominated Adviser)Liam Murray / Tony
Rawlinson |
Tel: +44 (0)20 7213
0880 |
N+1
Singer (Broker)Aubrey Powell / Jen Boorer
|
Tel: +44 (0)20 7496
3000 |
MacDougall
Biomedical Communications(US media contact)Chris Erdman /
Karen Sharma |
Tel: +1 781 235 3060
cerdman@macbiocom.comksharma@macbiocom.com |
Consilium
Strategic Communications (Financial public relations,
UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey
Neville |
Tel: +44 (0)20 3709
5700summit@consilium-comms.com |
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2023 to Mar 2024